Ligand Pharmaceuticals Announces Licensing Agreement With Nucorion Pharmaceuticals

Represented Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) in its strategic alliance and licensing agreement with Nucorion Pharmaceuticals for three programs that use Ligand’s Liver Targeting Prodrug technology. 

Nucorion is biotechnology company that focuses on the development of anti-cancer and anti-viral agents, initially targeted to the Chinese market. Ligand is a biopharmaceutical company that focuses on developing and or acquiring technologies that help pharmaceutical companies in discovering and creating medicines.